Insulet (PODD) AI Stock Analysis

• Market Cap: $23.29B
• Dividend Yield: N/A
• Average Volume (3M): 639.22K
• Price to Earnings (P/E): 100.7
• Beta (1Y): 1.00
• Revenue Growth: 25.99%
• EPS Growth: -40.46%
• Country: US
• Employees: 3,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.17
• Shares Outstanding: 70,392,530
• 10 Day Avg. Volume: 699,066
• 30 Day Avg. Volume: 639,216
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 9.53
• Enterprise Value/Gross Profit: 13.47
• Enterprise Value/Ebitda: 55.23
• 1Y Price Target: $360.00
• Price Target Upside: 8.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

• Rating: 76 Outperform
• Price Target: $370.00 ▲(11.84% Upside)

Insulet Corporation's strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company's robust revenue growth and improved leverage position, along with raised guidance, contribute significantly to its attractiveness. However, the high valuation and potential short-term overbought condition slightly temper the overall score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and effective business strategies, positioning Insulet for continued expansion in the diabetes management sector.

International Expansion

Robust international growth reflects successful market penetration strategies and enhances Insulet's global footprint, contributing to long-term revenue stability.

Leadership Changes

The new leadership appointments bring experienced executives to key roles, potentially driving strategic initiatives and operational efficiencies for sustained growth.

Negative Factors

Inventory Charges

Inventory-related charges indicate potential inefficiencies in supply chain management, which could impact profitability if not addressed.

Medicare Changes Impact

Possible changes in Medicare policies could affect Insulet's market dynamics, posing risks to revenue streams if competitive bidding impacts product coverage.

Decline in Net Profit Margin

A decline in net profit margin suggests pressure on profitability, which could affect Insulet's ability to reinvest in growth and innovation over time.

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation is a medical device company that specializes in the development and manufacturing of innovative insulin delivery systems, primarily for people with diabetes. The company is best known for its Omnipod Insulin Management System, which offers a tubeless, wearable insulin pump designed to improve the quality of life for individuals managing diabetes. Insulet operates in the healthcare sector, focusing on diabetes management and has expanded its product offerings to include advanced technology that integrates with continuous glucose monitoring systems.

How the Company Makes Money

Insulet generates revenue primarily through the sale of its Omnipod Insulin Management Systems and the related consumable products, such as insulin cartridges and infusion sets. The company has a subscription-based model for the consumables, which provides a recurring revenue stream as patients require ongoing supplies for their insulin delivery. Additionally, partnerships with healthcare providers and payers enhance its revenue model, as Insulet collaborates with insurance companies to ensure coverage for its products, thereby increasing accessibility for users. The company also invests in research and development to enhance its products, potentially leading to new revenue opportunities through innovation and improved technology integration with diabetes management solutions.

Insulet Financial Statement Overview

Summary

Insulet's financial performance is robust, with strong revenue growth and profitability metrics. The company has improved its leverage position and continues to generate healthy cash flows. While there is a slight decline in net profit margin, the overall financial health remains strong, positioning the company well in the medical devices industry.

Income Statement

Insulet has demonstrated strong revenue growth with a 7.3% increase in TTM, supported by a robust gross profit margin of 70.7%. The net profit margin has slightly decreased to 10% from the previous annual report's 20.2%, indicating some pressure on profitability. However, the EBIT and EBITDA margins remain healthy, reflecting efficient operations.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.96 in TTM, showing reduced leverage compared to previous periods. Return on equity is strong at 18.4%, indicating effective use of equity to generate profits. The equity ratio stands at 42.2%, suggesting a balanced capital structure with a solid equity base.

Cash Flow

Insulet's free cash flow growth is impressive at 35% in TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.50, showing moderate cash conversion efficiency. The free cash flow to net income ratio of 0.78 suggests a healthy cash flow relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.36B	2.07B	1.70B	1.31B	1.10B	904.40M
Gross Profit	1.67B	1.45B	1.16B	805.60M	752.10M	582.30M
EBITDA	407.30M	423.70M	323.60M	109.00M	139.60M	110.30M
Net Income	236.10M	418.30M	206.30M	4.60M	16.80M	6.80M
Balance Sheet
Total Assets	3.47B	3.09B	2.59B	2.25B	2.05B	1.87B
Cash, Cash Equivalents and Short-Term Investments	1.12B	953.40M	704.20M	674.70M	791.60M	947.60M
Total Debt	1.42B	1.42B	1.45B	1.43B	1.29B	1.08B
Total Liabilities	2.01B	1.88B	1.86B	1.77B	1.49B	1.27B
Stockholders Equity	1.46B	1.21B	732.70M	476.40M	556.30M	603.60M
Cash Flow
Free Cash Flow	392.60M	305.40M	70.10M	-38.30M	-190.80M	-82.50M
Operating Cash Flow	506.50M	430.30M	145.70M	119.00M	-68.10M	84.00M
Investing Cash Flow	-136.20M	-146.20M	-119.40M	-191.10M	-82.70M	14.00M
Financing Cash Flow	-78.90M	-28.10M	-13.60M	-40.30M	40.70M	605.50M

Insulet Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 330.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Neutral. The current price of 330.84 is below the 20-day moving average (MA) of 338.27, above the 50-day MA of 314.13, and above the 200-day MA of 287.58, indicating a neutral trend. The MACD of 4.25 indicates Positive momentum. The RSI at 50.24 is Neutral, neither overbought nor oversold. The STOCH value of 38.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PODD.

Insulet Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STE	79 Outperform	24.50B	37.72	9.29%	0.94%	2.47%	63.68%
PODD	76 Outperform	$23.29B	100.68	19.18%	―	25.99%	-40.46%
ZBH	74 Outperform	19.83B	24.37	6.57%	0.96%	4.11%	-14.43%
DXCM	71 Outperform	26.45B	47.22	22.21%	―	9.30%	-14.95%
PHG	56 Neutral	26.64B	-34.41	-5.85%	3.15%	-0.76%	-55.03%
TNDM	49 Neutral	849.35M	-4.07	-154.15%	―	25.84%	-47.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Insulet Corporate Events

Insulet Issues Redemption Notice for Convertible Notes

On June 6, 2025, Insulet Corporation amended its Credit Agreement to refinance $481.25 million in term loans, reducing the interest rate margin and maintaining similar terms to the previous loans. Additionally, Insulet issued a redemption notice on June 9, 2025, for its outstanding Convertible Senior Notes due 2026, with plans to redeem them by August 20, 2025, potentially impacting stock transactions as hedge positions are unwound.